本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 股票代码：000999 股票简称：华润三九 编号：2025—081 华润三九医药股份有限公司 关于控股子公司昆药集团担保事项的进展公告 一、担保情况概述 1. 担保事项履行的相关程序 被担保人：云南省丽江医药有限公司（以下简称"丽江医药"）、红河州佳宇药业有限 公司（以下简称"红河佳宇"）。上述被担保人为华润三九医药股份有限公司（以下简 称"华润三九"）控股子公司昆药集团股份有限公司（以下简称"昆药集团"）下属全 资子公司昆药集团医药商业有限公司（以下简称"昆药商业"）的控股子公司，不存在 关联担保。 本次担保金额及已实际为其提供的担保余额：本次为上述被担保人提供的担保金额为 1,620 万元，累计已实际为其提供的担保余额为 1,620 万元。 是否在前期预计额度内：是 本次担保是否有反担保：否 对外担保逾期的累计数量：无 保计划的公告》（2025-028）、《华润三九医药股份有限公司 2024 年年度股东会决议公告》 （2025-034）。 2. 担保进展概况 为支持昆药集团旗下控股子公司生产经 ...

1、公司 2025 年第三季度报告的编制和审议程序符合法律、法规和公司章程的规定； 股票代码：000999 股票简称：华润三九 编号：2025—079 华润三九医药股份有限公司 2025 年第八次监事会会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"公司"或"华润三九"）监事会 2025 年第 八次会议于 2025 年 10 月 23 日在华润三九医药工业园综合办公中心 107 会议室召开。 会议通知以书面方式于 2025 年 10 月 13 日发出。会议由监事会主席陶然先生主持，本 次会议应到监事 5 人，实到监事 5 人。本次会议的召开及程序符合《公司法》和《公司 章程》的规定，会议合法有效。会议以投票方式审议通过了以下议案，并形成决议： 一、关于公司 2025 年第三季度报告的议案 华润三九医药股份有限公司（以下简称"公司"）监事会对公司 2025 年第三季度报 告发表审核意见如下： 2、公司 2025 年第三季度报告的内容和格式符合中国证监会和深圳证券交易所的各 项规定，所记载的信息真实地反映出公司 2 ...

股票代码：000999 股票简称：华润三九 编号：2025—078 华润三九医药股份有限公司 2025 年第十二次董事会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"公司"或"华润三九"）董事会 2025 年 第十二次会议于 2025 年 10 月 23 日在华润三九医药工业园综合办公中心 107 会议室召 开。会议通知以书面方式于 2025 年 10 月 13 日发出。本次会议应到董事 11 人，实到董 事 11 人。本次会议由公司董事长邱华伟先生主持，公司监事会成员和部分高级管理人 员列席会议。本次会议的召开及程序符合《公司法》和《公司章程》的规定，会议合法 有效。会议以投票方式审议通过了以下议案，并形成决议： 一、 关于公司 2025 年第三季度报告的议案 本议案提交董事会前已经公司董事会审计委员会审议通过。 详细内容请参见《华润三九医药股份有限公司 2025 年第三季度报告》（2025-080）。 表决结果：11 票同意，0 票反对，0 票弃权，审议通过。 二、 关于确定公司管理团队薪酬的议案 关联董 ...

Core Viewpoint - The Medical Health Index (980016) closed at 6646.6 points, down 0.3%, with a trading volume of 19.922 billion yuan and a turnover rate of 0.75% on October 23 [1] Group 1: Index Performance - Among the constituent stocks of the Medical Health Index, 16 stocks rose while 31 stocks fell, with Kanglong Chemical leading the gainers at 1.55% and Te Bao Biological leading the decliners at 6.07% [1] - The top ten constituent stocks of the Medical Health Index include: - WuXi AppTec (14.37% weight, latest price 101.90, market cap 304.045 billion yuan) - Hengrui Medicine (11.45% weight, latest price 65.14, market cap 432.347 billion yuan) - Mindray Medical (8.07% weight, latest price 221.80, market cap 268.920 billion yuan) [1] Group 2: Capital Flow - The net outflow of main funds from the constituent stocks of the Medical Health Index totaled 1.072 billion yuan, while retail investors saw a net inflow of 955 million yuan [3] - Detailed capital flow for key stocks includes: - Mindray Medical: Main net inflow of 66.9479 million yuan, retail net inflow of 3.6088 million yuan - Te Bao Biological: Main net inflow of 29.0966 million yuan, retail net outflow of 41.3737 million yuan [3]

Core Viewpoint - The Chinese medicine sector is experiencing a mixed performance, with the Chinese medicine ETF (560080) showing significant net inflows and a growing fund size, despite the overall index performance being negative for the year [1][4]. Group 1: Market Performance - The Chinese medicine ETF (560080) saw a slight decline of 0.46% with a total trading volume of 116 million yuan on the day [1]. - The ETF has attracted a net inflow of 192 million yuan yesterday, ranking it among the top 9 in the market, and has seen a total net inflow exceeding 600 million yuan over the past 16 days [1]. - The Chinese medicine index has a year-to-date return of -2.53%, with a decline of 8.13% projected for 2024 [3]. Group 2: Valuation Metrics - As of October 22, the TTM price-to-earnings (PE) ratio of the Chinese medicine ETF (560080) is 25.22, indicating that the index is cheaper than 77% of the time over the past decade [4]. - The current PE ratio is close to the calculated opportunity value, suggesting a favorable valuation for potential investment [4]. Group 3: Company Performance - The component stocks of the Chinese medicine ETF exhibited mixed results, with companies like Yunnan Baiyao and Pianzaihuang showing slight increases, while others like Zhongsheng Pharmaceutical and Darentang experienced declines exceeding 4% [5]. - The performance of major brands in the OTC market is expected to improve, with companies like Huazhong Sanjiu, Dong'e Ejiao, and Yunnan Baiyao being highlighted as stable performers [8]. Group 4: Industry Outlook - The Chinese medicine sector is under short-term pressure due to various factors, but there is optimism for operational improvements in the second half of the year [7]. - The market is closely monitoring the impact of external policies, including price governance and the collection of traditional Chinese medicine, which may influence future performance [7][9]. - The industry is expected to benefit from a recovery in consumer demand, driven by macroeconomic improvements and an aging population [10].

Core Points - The Shenzhen State-Owned Enterprises ESGR Index (470055) closed at 1592.08 points, down 0.02%, with a trading volume of 30.197 billion yuan and a turnover rate of 0.94% [1] - Among the index constituents, 24 stocks rose while 21 fell, with Tongyu Heavy Industry leading the gainers at 3.95% and Guangdong Hongda leading the decliners at 5.35% [1] Index Constituents Summary - The top ten constituents of the Shenzhen State-Owned Enterprises ESGR Index are as follows: - Hikvision (sz002415): Weight 9.64%, Latest Price 33.47, Change 2.73%, Market Cap 306.748 billion yuan, Industry: Computer [1] - BOE Technology Group (sz000725): Weight 9.31%, Latest Price 4.02, Change 0.00%, Market Cap 150.404 billion yuan, Industry: Electronics [1] - Wuliangye Yibin (sz000858): Weight 8.62%, Latest Price 120.10, Change -0.35%, Market Cap 466.181 billion yuan, Industry: Food & Beverage [1] - Inspur Information (sz000977): Weight 7.30%, Latest Price 66.52, Change -1.03%, Market Cap 97.926 billion yuan, Industry: Computer [1] - Weichai Power (sz000338): Weight 6.78%, Latest Price 14.63, Change 0.34%, Market Cap 127.480 billion yuan, Industry: Automotive [1] - AVIC Optoelectronics (sz002179): Weight 4.48%, Latest Price 37.17, Change -1.43%, Market Cap 78.736 billion yuan, Industry: Defense [1] - Shenwan Hongyuan (sz000166): Weight 4.14%, Latest Price 5.37, Change 0.00%, Market Cap 134.464 billion yuan, Industry: Non-Bank Financial [1] - Yunnan Aluminum (sz000807): Weight 4.08%, Latest Price 22.18, Change 0.82%, Market Cap 76.919 billion yuan, Industry: Nonferrous Metals [1] - Changchun High & New Technology (sz000661): Weight 3.73%, Latest Price 119.11, Change -0.97%, Market Cap 48.589 billion yuan, Industry: Pharmaceuticals [1] - China Merchants Shekou (sz001979): Weight 3.31%, Latest Price 9.88, Change -1.50%, Market Cap 89.521 billion yuan, Industry: Real Estate [1] Capital Flow Analysis - The net outflow of main funds from the ESGR index constituents totaled 340 million yuan, while retail investors saw a net inflow of 126 million yuan [1] - The detailed capital flow for key stocks includes: - Hikvision: Main net inflow 374 million yuan, retail net outflow 29.5 million yuan [2] - Zhongcai Technology: Main net inflow 141 million yuan, retail net outflow 18.8 million yuan [2] - Yunnan Aluminum: Main net inflow 137 million yuan, retail net outflow 121 million yuan [2] - Weichai Power: Main net inflow 27.6 million yuan, retail net outflow 2.33 million yuan [2]

Core Insights - The traditional Chinese medicine sector experienced a slight increase of 0.16% on October 22, with Te Yi Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Te Yi Pharmaceutical (002728) closed at 11.09, up 10.02% with a trading volume of 1.1334 million shares and a transaction value of 1.201 billion [1] - Other notable gainers included Zhongsheng Pharmaceutical (002317) with a 5.22% increase, closing at 19.35, and Xinbang Pharmaceutical (002390) with a 3.89% increase, closing at 4.01 [1] - Conversely, stocks like Fangsheng Pharmaceutical (603998) and ST Xiangxue (300147) saw declines of 3.06% and 2.86%, respectively [2] Capital Flow - The traditional Chinese medicine sector saw a net outflow of 237 million in institutional funds, while retail investors contributed a net inflow of 235 million [2] - The table of capital flow indicates that Te Yi Pharmaceutical had a significant net inflow of 196 million from institutional investors, despite a net outflow from retail investors [3] - Other companies like Xinbang Pharmaceutical and Zhongsheng Pharmaceutical also experienced mixed capital flows, with varying degrees of institutional and retail investor activity [3]

Summary of Key Points from Conference Call Records Industry Overview - The innovative drug sector is experiencing a strategic opportunity after adjustments, with leading companies like Innovent Biologics and Baillie Tianheng showing solid fundamentals, while smaller companies need to focus on fundamental performance [1][4] - The medical device sector is seeing inventory clearance in Q3, marking a turning point for performance, with high-end equipment having significant import substitution potential [1][5] - The IVD (In Vitro Diagnostics) sector faces policy pressures but shows a notable increase in domestic market share, with companies expected to emerge from pressure in Q4 [1][6] Key Insights and Arguments - The pharmaceutical industry has ranked 11th among 31 sectors this year, with an 18.85% increase, indicating a potential rebound in innovative drugs and related sectors after a period of adjustment [2] - The innovative drug sector has seen a 20% to 30% adjustment among leading companies, while smaller companies have faced larger declines, with a potential for recovery driven by clinical trial data from the ESMO conference [3][4] - The IVD market in China is growing rapidly, with a compound annual growth rate (CAGR) of 18.6% from 2021 to 2024, indicating a strong domestic replacement trend [13][14] Notable Developments in Specific Companies - **Jiuzhitang**: Recognized for its stem cell research pipeline, with potential market capitalization growth from 5 to 15 billion RMB based on its projects [7] - **Kangyuan**: Expected to see a recovery in net profit to 400 million RMB, with multiple innovative projects enhancing its growth potential [7] - **Kanglong Chemical**: Core profits are largely unaffected by tariffs and geopolitical issues, with a projected market value of 80 billion RMB by 2026 [11][12] - **Pro Pharmaceutical**: Anticipated to enter a new growth cycle with a projected compound annual growth rate exceeding 20% from 2025 to 2027 [13] Market Trends and Future Expectations - The medical device sector is expected to see performance improvements in Q3 and Q4 due to inventory clearance and favorable bidding data [5] - High-value consumables are experiencing significant growth, particularly in neurosurgery and orthopedics, with companies like Maipu Medical and Chunli rapidly expanding overseas [5][6] - The IVD market is projected to grow from 5.9 billion USD in 2023 to 8 billion USD by 2028, with a CAGR of 6.3%, outpacing global growth [16] Strategic Moves and Recommendations - Companies are advised to focus on high-quality products and overseas expansion strategies, with successful examples including Mindray and Jiuzhitang, which have established strong international operations [17][18] - The strategic shift of Huazhong Sanjiu towards innovative drug development and partnerships indicates a long-term growth potential, with expected double-digit revenue growth in 2025 [9][10] Additional Important Insights - The IVD sector's domestic market share is increasing, with significant growth in various diagnostic fields, indicating a robust trend towards local production [15] - The overall sentiment in the pharmaceutical industry is cautiously optimistic, with potential for recovery and growth in innovative drugs and medical devices as market conditions improve [2][3]

Core Viewpoint - The Chinese traditional medicine sector is experiencing a resurgence, with the Chinese Medicine ETF (560080) showing strong performance and attracting significant capital inflows, indicating investor confidence in the sector's growth potential [1][6]. Market Performance - The Chinese Medicine ETF (560080) rose by 0.83%, marking a two-day consecutive increase, with total trading volume exceeding 1 billion yuan [1]. - The ETF has seen a net inflow of over 250 million yuan in the last 10 days, bringing its total size to over 2.6 billion yuan, leading its peers significantly [1]. - Despite the recent gains, the traditional medicine index remains in negative territory for the year, with a year-to-date decline of 1.92% and a drop of 8.13% projected for 2024 [2]. Component Stocks - Key stocks within the Chinese Medicine ETF showed positive movements, with notable gains from Zhaoli Pharmaceutical (up 4.21%), Zhongsheng Pharmaceutical (up 3.99%), and Jilin Aodong (up 2.73%) [4]. - The overall performance of component stocks reflects a mixed sentiment, with some stocks experiencing slight declines [4]. Valuation Metrics - The TTM price-to-earnings ratio for the Chinese Medicine ETF is 24.97, which is at the 21.38% percentile of the past decade, suggesting a favorable valuation compared to historical levels [5]. Investment Trends - Leveraged funds are increasingly using the ETF to invest in the high-value Chinese traditional medicine sector, with the latest financing balance exceeding 88 million yuan, maintaining historical highs [6]. - Institutional investors are actively seeking opportunities in the sector, focusing on innovation and transformation strategies to create new growth avenues [8]. Regulatory Environment - The ongoing adjustments to the National Essential Medicines List are expected to favor traditional Chinese medicine, with potential increases in the number of TCM products included [9]. - The adjustments are anticipated to enhance the market presence of TCM, aligning with the government's focus on integrating traditional and modern medicine [9].

Market Overview - The Chinese traditional medicine sector rose by 0.84% on October 15, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Zhendong Pharmaceutical (300158) closed at 6.93, with a gain of 5.64% and a trading volume of 913,500 shares, amounting to a transaction value of 636 million yuan [1] - Tianmu Pharmaceutical (600671) closed at 19.62, up 5.31%, with a trading volume of 73,800 shares [1] - Zuoli Pharmaceutical (300181) closed at 19.07, increasing by 4.21%, with a trading volume of 283,300 shares [1] - Other notable performers include Zhongsheng Pharmaceutical (002317) and Xintian Pharmaceutical (002873), with gains of 3.99% and 3.70% respectively [1] Capital Flow - The traditional medicine sector saw a net inflow of 378 million yuan from institutional investors, while retail investors experienced a net outflow of 276 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors showing confidence while retail investors withdrew funds [2] Individual Stock Capital Flow - Zuoli Pharmaceutical (300181) had a net inflow of 76.71 million yuan from institutional investors, while retail investors saw a net outflow of 38.14 million yuan [3] - Zhendong Pharmaceutical (300158) experienced a net inflow of 56.45 million yuan from institutional investors, with retail investors withdrawing 51.44 million yuan [3] - Yunnan Baiyao (000538) had a net inflow of 52.53 million yuan from institutional investors, but retail investors withdrew 56.48 million yuan [3]